GENERAL
Novartis India Terminates Sales Pact With Dr Reddy’s For Key Medicines
Novartis India Ltd has decided to terminate its exclusive distribution and promotion agreement with Dr. Reddy’s Laboratories Ltd (DRL), bringing an end to a strategic partnership signed in 2022 for the marketing and sale of several established medicine brands in India. The company’s Board of Directors has approved the termination of the distribution and promotion […]
Sajan C Kumar
·
Aug 7, 2026
GENERAL
AstraZeneca Pharma India Scales Up Innovation, Gets 11 Approvals In FY26
AstraZeneca Pharma India Ltd is strengthening its leadership across key therapy areas by accelerating the introduction of innovative medicines, investing in healthcare infrastructure and expanding partnerships to improve early diagnosis and patient access, according to its Managing Director and Country President Praveen Rao Akkinepally. In his message to shareholders in the company’s Annual Report 2026, […]
CW Bureau
·
Jul 19, 2026
GENERAL
Aurobindo Eyes $494-Mn US Market With Launch Of Tofacitinib Generic
Aurobindo Pharma has strengthened its presence in the lucrative US generics market after receiving final approval from the US Food and Drug Administration (USFDA) for Tofacitinib tablets in 5 mg and 10 mg strengths, opening the door to a market worth nearly $500 million annually. The approval allows the company to manufacture and market a […]
CW Bureau
·
Jun 4, 2026
GENERAL
Sun Pharma Bets On R&D, Compliance Upgrades To Speed Up Growth Engine
Sun Pharmaceutical Industries is sharpening its focus on research and development, regulatory compliance, and manufacturing capabilities as it targets high single-digit consolidated revenue growth in FY27, Chairman Dilip Shanghvi said during the company’s latest earnings call. The pharmaceutical major continues to invest heavily in strengthening both its global generics and innovative medicines businesses, with R&D […]
CW Bureau
·
May 30, 2026
GENERAL
Dr Reddy’s Oral Semaglutide Brand Obeda For Type 2 Diabetes Launched
Dr Reddy’s Laboratories has launched its oral semaglutide biosimilar for the treatment of Type 2 diabetes mellitus in India under the brand name Obeda, strengthening its presence in the fast-growing GLP-1 therapy segment. The launch follows the company’s recent generic semaglutide injection launches in India and Canada, positioning Dr Reddy’s as a full-stack player in […]
CW Bureau
·
May 20, 2026
